scholarly journals Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment

Oncotarget ◽  
2016 ◽  
Vol 7 (44) ◽  
pp. 71782-71789 ◽  
Author(s):  
Fumio Imamura ◽  
Junji Uchida ◽  
Yoji Kukita ◽  
Toru Kumagai ◽  
Kazumi Nishino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Cancer Treatment ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Circulating Tumor Dna ◽  
Lung Cancer Treatment ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Tumor Dna

scholarly journals Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1590
Author(s):  
Kenichi Suda ◽  
Tetsuya Mitsudomi
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Molecular Mechanisms ◽  
Kinase Inhibitors ◽  
Drug Tolerance ◽  
Lung Cancers ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutated

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) serve as the standard of care for the first-line treatment of patients with lung cancers with EGFR-activating mutations. However, the acquisition of resistance to EGFR TKIs is almost inevitable, with extremely rare exceptions, and drug-tolerant cells (DTCs) that demonstrate reversible drug insensitivity and that survive the early phase of TKI exposure are hypothesized to be an important source of cancer cells that eventually acquire irreversible resistance. Numerous studies on the molecular mechanisms of drug tolerance of EGFR-mutated lung cancers employ lung cancer cell lines as models. Here, we reviewed these studies to generally describe the features, potential origins, and candidate molecular mechanisms of DTCs. The rapid development of an optimal treatment for EGFR-mutated lung cancer will require a better understanding of the underlying molecular mechanisms of the drug insensitivity of DTCs.

scholarly journals V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors

2014 ◽  
Vol 9 (9) ◽  
pp. 1377-1384 ◽  
Author(s):  
Satsuki Matsushima ◽  
Kouki Ohtsuka ◽  
Hiroaki Ohnishi ◽  
Masachika Fujiwara ◽  
Hiroyuki Nakamura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Egfr Mutation ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors

EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19117-19117
Author(s):  
D. M. Kowalski ◽  
M. Krzakowski ◽  
P. Jaskiewicz ◽  
A. Janowicz-Zebrowska ◽  
M. Glogowski
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document